A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 974 participants.

Also called NCT06948422

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose screening
Phase
Phase 3
Enrolled
  • 974 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06948422
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06948422. Randomized; double masking; primary purpose screening. Start 2025-04-30 (actual); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Condition
Hypertension
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06948422
Content hash
bf609dfc95c8502293a073ce141cf148ecfa938a691fee4ea47139e4dcf96022